Advertisement
Advertisement

AUPH

AUPH logo

Aurinia Pharmaceuticals Inc

15.23
USD
Sponsored
+0.09
+0.59%
May 08, 16:00 UTC -4
Closed
exchange

Pre-Market

15.26

+0.03
+0.18%

Aurinia Pharmaceuticals Inc Profile

About

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Info & Links

CEO

Peter Greenleaf

Headquarters

14315 - 118 AVENUE, SUITE 140
EDMONTON, A0 T5L 4S6, CANADA

Industry

Medical Drugs

Sector

Medical

Website

www.auriniapharma.com

Auditor

PricewaterhouseCoopers LLP

Share holders

110

Employees

128

Aurinia Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

1.96B

Enterprise Value

1.99B

Enterprise Value/EBITDA(ttm)

13.30

Price to Earnings Ratio(ttm)

19.70

Price to Sales(ttm)

7.50

Price to Book(mrq)

3.62

Price to Cash(ytd)

15.75

Profitability

Gross Margin(ttm)

88.39%

Operating Margin(ttm)

39.60%

Profit Margin(ttm)

96.10%

Return on Equity(ttm)

27.47%

Return on Invested Capital(ttm)

51.94%

Return on Assets(ttm)

19.61%

Income Statement

Revenue(ttm)

298.30M

Revenue Per Share(ttm)

--

Gross Profit(ttm)

267.70M

EBITDA(ttm)3

149.28M

Net Income Available to Common(ttm)

298.21M

Diluted EPS(ttm)

2.08

Share Statistics

Beta (5Y Monthly)

1.51

52-Week Change

90.38%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

116.75M

% Held by Insiders

12.20%

% Held by Institutions

36.83%

Balance Sheet

Total Cash(mrq)

378.78M

Total Cash Per Share(mrq)

--

Total Debt(mrq)

64.70M

Total Debt/Equity(mrq)

11.84%

Current Ratio(mrq)

5.25%

Quick Ratio(mrq)

4.76%

Book Value Per Share(mrq)

4.39

Cash Flow

Operating Cash Flow Per Share(ytd)

0.98

Free Cash Flow(ytd)

135.41M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement